News

Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.

The stock is down about 13% from its 52-week high.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

The shingles vaccine costs nothing under Medicare Part D, yet thousands of beneficiaries walk out of their doctor's office owing hundreds of dollars for the exact same shot. The billing system has a gap, and most patients have no idea it exists until they're already holding the receipt.

CVS Health is advancing Aetna's profitability turnaround, supported by stronger Health Care Benefits results, an improved MBR and operational initiatives.

CVS Health stock has delivered a strong 64.8% return over the past three years, and the current valuation picture is not a clear bargain or a clear stretch. Recent gains sit alongside a mixed value score and fresh headlines around its health insurance and compliance record, which give investors a few moving parts to weigh. The 64.8% three year return highlights how much value the market has already credited to CVS Health, so fresh buyers now have to judge whether that past performance still...

CVS Health (NYSE:CVS) announced that updated 2026-2027 COVID-19 vaccines are now available at CVS Pharmacy and MinuteClinic locations across the United States. The company is offering the new vaccines nationwide, with appointments and walk-in options across its retail and clinic network. CVS Health is integrating COVID-19 shots with other vaccinations, aiming to streamline access to multiple immunizations in a single visit. This kind of broad vaccine rollout highlights how large pharmacy...

A caller on the September 2 episode of Mad Money noted that CVS Health Corporation (NYSE:CVS) is up 21% this year, sports a 3% dividend, and trades at a 28 valuation compared to its 54 average. Pointing to raised guidance, higher price targets, and a massive capital plan, they asked if it makes sense to […]

CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CVS Health has outperformed the broader market over the past year, while analysts remain highly bullish on its future prospects.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.

UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.

The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.

The founders of Kemo Sabe, Slick Chicks, Sunhome Saunas and more share important lessons on surviving year one in small business. Plus, everything you need to know before the business tax filing extension deadline hits this year.

The founders of Kemo Sabe, Slick Chicks, Sunhome Saunas and more share important lessons on surviving year one in small business. Plus, everything you need to know before the business tax filing extension deadline hits this year.

CVS Health's strong cash generation, higher operating cash flow outlook and disciplined capital deployment support continued deleveraging in 2026.

CVS Health (CVS) recently raised its 2026 adjusted earnings per share guidance to a range of US$7.90 to US$8.10 and outlined plans to invest US$20 billion in healthcare technology and data infrastructure. Those guidance comments and investment plans have landed in a stock that has already seen momentum pick up. CVS Health’s 1 day share price return of 3.93% and 7 day return of 5.06% come after a 30 day decline of 6.54%, while the year to date share price return of 21.80% and 1 year total...

Wall Street is warming to the prospects of the healthcare giant.

Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Consensus knocks a quarter off the health insurer's earnings multiple over two years, part of it measurement, and almost none of it from selling more coverage.

Sen. Elizabeth Warren (D-Mass.) warned that growing corporate consolidation is giving a small group of powerful companies and CEOs outsized influence over Americans’ everyday choices, urging regulators to block mega-mergers. Warren Targets Corporate Consolidation On Saturday, in a post on...

Weight loss drug consumers get a Medicare cost break, but it has a deadline.

UnitedHealth Group's stronger six-month return, improving UnitedHealthcare and Optum results and attractive valuation make it the better buy.

The healthcare giant's shares have pulled back more than 12% over the past month.

Its market-shock drawdowns have been ordinary in depth, and some of its longest waits back to the old high came after falls the index barely noticed.

Cigna, Molina, and at least 10 other carriers will stop selling Obamacare plans, affecting hundreds of thousands of enrollees in more than 20 states

The healthcare giant sent a fortune back to its owners, but the market yawned. Here’s the real accounting of what that cash bought, and what it didn't.

A powerful healthcare business model is facing fresh political pressure

CVS Health carries strong pharmacy momentum into H2 2026, with rising prescription volume, Rite Aid gains and higher profit.

Both CVS and Intel delivered real turnaround results in 2026, then both stocks got punished for very different reasons. For a retiree drawing income from a portfolio, one of those reasons matters far more than the other.